Dechra Pharmaceuticals records rise in revenues and profits

Dechra Pharmaceuticals raised its dividend by 15.1 per cent as the company achieved higher revenues and profits during the second half of 2012.

Dechra Pharmaceuticals raised its dividend by 15.1 per cent as the company achieved higher revenues and profits during the second half of 2012.

The veterinary medicines company returned an interim dividend per share of 4.34p, compared to 3.77p for the same period a year earlier.

Group revenues climbed 20.4% year-on-year to £252.2m for the half year while profits before tax soared 29.25 to £11.5m.

Results were driven by strong performance of licensed branded veterinary products in specialist pet diets in key segments in Europe and the US.

Contract manufacturing saw double digit sales growth while the group's services segment realised solid revenues and a modest improvement in operating margin.

Dechra began to see rewards from the successful integration of Eurovet Animal Health which the company acquired last May. Eurovet is a Netherlands-based business which operates in the companion animal pharmaceuticals and farm animal pharmaceuticals markets.

"The first phase of the integration has progressed in line with our strategy and is delivering the expected cost and revenue synergies," the company said.

Net borrowings were up £102m at the end of the year, compared to £87m at June 30th and £46.1m at the end of 2011.

Operating profits jumped 37.3% to £15.1m while basic earnings per share increased 6.9% to 9.91p.

The firm's outlook for the year ahead was positive as trading was expected to remain robust. However, the company said it was cautious given the economic environment, particularly in European markets.

Dechra said bad weather also hit sales in the service sector in January but anticipates the segment will bounce back.

"The group continues to deliver its strategic objectives; with additional synergies from the Eurovet acquisition, new product introductions, improved efficiency and international expansion we remain well positioned to maintain our strong growth."

RD

Recommended

Should you buy Vodafone shares, or steer clear?
Share tips

Should you buy Vodafone shares, or steer clear?

Vodafone grew revenue by 4% and profit by 11% last year, and offers investors a 6.4% dividend yield. So should you buy Vodafone shares? Rupert Hargrea…
17 May 2022
Melrose Industries: a British manufacturer that is well-placed for recovery
Share tips

Melrose Industries: a British manufacturer that is well-placed for recovery

Melrose, the aerospace and automotive manufacturer, has been hit by the pandemic, but the shares are unduly cheap says David J Stevenson.
17 May 2022
Avoid easyJet shares – there are better airlines to invest in
Share tips

Avoid easyJet shares – there are better airlines to invest in

EasyJet used to be one of Europe’s most impressive airlines. But now it is facing challenges on all fronts and losing out to the competition. Rupert …
16 May 2022
Britain’s ten most-hated shares – w/e 13 May
Stocks and shares

Britain’s ten most-hated shares – w/e 13 May

Rupert Hargreaves looks at Britain's ten-most hated shares, and what short-sellers are looking right now.
16 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
Is the oil market heading for a supply glut?
Oil

Is the oil market heading for a supply glut?

Many people assume that the high oil price is here to stay – and could well go higher. But we’ve been here before, says Max King. History suggests tha…
16 May 2022
High inflation will fade – here’s why
Inflation

High inflation will fade – here’s why

Many people expect high inflation to persist for a long time. But that might not be true, says Max King. Inflation may fall faster than expected – and…
13 May 2022